312 related articles for article (PubMed ID: 30125350)
1. Clonal heterogeneity influences drug responsiveness in renal cancer assessed by ex vivo drug testing of multiple patient-derived cancer cells.
Saeed K; Ojamies P; Pellinen T; Eldfors S; Turkki R; Lundin J; Järvinen P; Nisen H; Taari K; Af Hällström TM; Rannikko A; Mirtti T; Kallioniemi O; Östling P
Int J Cancer; 2019 Mar; 144(6):1356-1366. PubMed ID: 30125350
[TBL] [Abstract][Full Text] [Related]
2. Cell Culture System for Analysis of Genetic Heterogeneity Within Hepatocellular Carcinomas and Response to Pharmacologic Agents.
Gao Q; Wang ZC; Duan M; Lin YH; Zhou XY; Worthley DL; Wang XY; Niu G; Xia Y; Deng M; Liu LZ; Shi JY; Yang LX; Zhang S; Ding ZB; Zhou J; Liang CM; Cao Y; Xiong L; Xi R; Shi YY; Fan J
Gastroenterology; 2017 Jan; 152(1):232-242.e4. PubMed ID: 27639803
[TBL] [Abstract][Full Text] [Related]
3. Mechanisms of acquired resistance to rapalogs in metastatic renal cell carcinoma.
Hamieh L; Choueiri TK; Ogórek B; Khabibullin D; Rosebrock D; Livitz D; Fay A; Pignon JC; McDermott DF; Agarwal N; Gao W; Signoretti S; Kwiatkowski DJ
PLoS Genet; 2018 Sep; 14(9):e1007679. PubMed ID: 30256787
[TBL] [Abstract][Full Text] [Related]
4. Ex Vivo Drug Testing in Patient-derived Papillary Renal Cancer Cells Reveals EGFR and the BCL2 Family as Therapeutic Targets.
Angori S; Banaei-Esfahani A; Mühlbauer K; Bolck HA; Kahraman A; Karakulak T; Poyet C; Feodoroff M; Potdar S; Kallioniemi O; Pietiäinen V; Schraml P; Moch H
Eur Urol Focus; 2023 Sep; 9(5):751-759. PubMed ID: 36933996
[TBL] [Abstract][Full Text] [Related]
5. Functional and genomic characterization of patient-derived xenograft model to study the adaptation to mTORC1 inhibitor in clear cell renal cell carcinoma.
Sakamoto H; Yamasaki T; Sumiyoshi T; Takeda M; Shibasaki N; Utsunomiya N; Arakaki R; Akamatsu S; Kobayashi T; Inoue T; Kamba T; Nakamura E; Ogawa O
Cancer Med; 2021 Jan; 10(1):119-134. PubMed ID: 33107222
[TBL] [Abstract][Full Text] [Related]
6. Tracing Clonal Dynamics Reveals that Two- and Three-dimensional Patient-derived Cell Models Capture Tumor Heterogeneity of Clear Cell Renal Cell Carcinoma.
Bolck HA; Corrò C; Kahraman A; von Teichman A; Toussaint NC; Kuipers J; Chiovaro F; Koelzer VH; Pauli C; Moritz W; Bode PK; Rechsteiner M; Beerenwinkel N; Schraml P; Moch H
Eur Urol Focus; 2021 Jan; 7(1):152-162. PubMed ID: 31266731
[TBL] [Abstract][Full Text] [Related]
7. Wide spetcrum mutational analysis of metastatic renal cell cancer: a retrospective next generation sequencing approach.
Fiorentino M; Gruppioni E; Massari F; Giunchi F; Altimari A; Ciccarese C; Bimbatti D; Scarpa A; Iacovelli R; Porta C; Virinder S; Tortora G; Artibani W; Schiavina R; Ardizzoni A; Brunelli M; Knuutila S; Martignoni G
Oncotarget; 2017 Jan; 8(5):7328-7335. PubMed ID: 27741505
[TBL] [Abstract][Full Text] [Related]
8. Higher expression of XPF is a critical factor in intrinsic chemotherapy resistance of human renal cell carcinoma.
Zhang Q; Shi J; Yuan F; Wang H; Fu W; Pan J; Huang Y; Yu J; Yang J; Chen Z
Int J Cancer; 2016 Dec; 139(12):2827-2837. PubMed ID: 27542841
[TBL] [Abstract][Full Text] [Related]
9. Sunitinib, sorafenib and mTOR inhibitors in renal cancer.
Radulovic S; Bjelogrlic SK
J BUON; 2007 Sep; 12 Suppl 1():S151-62. PubMed ID: 17935273
[TBL] [Abstract][Full Text] [Related]
10. Development and characterization of clinically relevant tumor models from patients with renal cell carcinoma.
Karam JA; Zhang XY; Tamboli P; Margulis V; Wang H; Abel EJ; Culp SH; Wood CG
Eur Urol; 2011 Apr; 59(4):619-28. PubMed ID: 21167632
[TBL] [Abstract][Full Text] [Related]
11. Exceptional response to everolimus in a novel tuberous sclerosis complex-2 mutation-associated metastatic renal-cell carcinoma.
Alsidawi S; Kasi PM
Cold Spring Harb Mol Case Stud; 2018 Apr; 4(2):. PubMed ID: 29610387
[TBL] [Abstract][Full Text] [Related]
12. In vitro evidence for a new therapeutic approach in renal cell carcinoma.
Pittoggi C; Martis G; Mastrangeli G; Mastrangeli B; Spadafora C
Int Braz J Urol; 2008; 34(4):492-502. PubMed ID: 18778501
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of MDM2 Re-Sensitizes Rapamycin Resistant Renal Cancer Cells via the Activation of p53.
Tian X; Dai S; Sun J; Jiang S; Sui C; Meng F; Li Y; Fu L; Jiang T; Wang Y; Su J; Jiang Y
Cell Physiol Biochem; 2016; 39(5):2088-2098. PubMed ID: 27825169
[TBL] [Abstract][Full Text] [Related]
14. Topotecan (Hycamtin) responsiveness in human renal carcinoma cell lines of the clear cell and papillary types.
Ramp U; Mahotka C; Kalinski T; Ebel E; Gabbert HE; Gerharz CD
Anticancer Res; 2001; 21(5):3509-17. PubMed ID: 11848517
[TBL] [Abstract][Full Text] [Related]
15. Patient-derived cell models as preclinical tools for genome-directed targeted therapy.
Lee JY; Kim SY; Park C; Kim NK; Jang J; Park K; Yi JH; Hong M; Ahn T; Rath O; Schueler J; Kim ST; Do IG; Lee S; Park SH; Ji YI; Kim D; Park JO; Park YS; Kang WK; Kim KM; Park WY; Lim HY; Lee J
Oncotarget; 2015 Sep; 6(28):25619-30. PubMed ID: 26296973
[TBL] [Abstract][Full Text] [Related]
16. Sunitinib Treatment Exacerbates Intratumoral Heterogeneity in Metastatic Renal Cancer.
Stewart GD; O'Mahony FC; Laird A; Eory L; Lubbock AL; Mackay A; Nanda J; O'Donnell M; Mullen P; McNeill SA; Riddick AC; Berney D; Bex A; Aitchison M; Overton IM; Harrison DJ; Powles T
Clin Cancer Res; 2015 Sep; 21(18):4212-23. PubMed ID: 26015515
[TBL] [Abstract][Full Text] [Related]
17. Spheroid Culture Differentially Affects Cancer Cell Sensitivity to Drugs in Melanoma and RCC Models.
Filipiak-Duliban A; Brodaczewska K; Kajdasz A; Kieda C
Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163092
[TBL] [Abstract][Full Text] [Related]
18. An organoid biobank for childhood kidney cancers that captures disease and tissue heterogeneity.
Calandrini C; Schutgens F; Oka R; Margaritis T; Candelli T; Mathijsen L; Ammerlaan C; van Ineveld RL; Derakhshan S; de Haan S; Dolman E; Lijnzaad P; Custers L; Begthel H; Kerstens HHD; Visser LL; Rookmaaker M; Verhaar M; Tytgat GAM; Kemmeren P; de Krijger RR; Al-Saadi R; Pritchard-Jones K; Kool M; Rios AC; van den Heuvel-Eibrink MM; Molenaar JJ; van Boxtel R; Holstege FCP; Clevers H; Drost J
Nat Commun; 2020 Mar; 11(1):1310. PubMed ID: 32161258
[TBL] [Abstract][Full Text] [Related]
19. Tracking sub-clonal TP53 mutated tumor cells in human metastatic renal cell carcinoma.
Bousquet G; El Bouchtaoui M; Leboeuf C; Battistella M; Varna M; Ferreira I; Plassa LF; Hamdan D; Bertheau P; Feugeas JP; Damotte D; Janin A
Oncotarget; 2015 Aug; 6(22):19279-89. PubMed ID: 26002555
[TBL] [Abstract][Full Text] [Related]
20. Silencing Livin induces apoptotic and autophagic cell death, increasing chemotherapeutic sensitivity to cisplatin of renal carcinoma cells.
Wang Z; Liu S; Ding K; Ding S; Li C; Lu J; Gao D; Zhang T; Bi D
Tumour Biol; 2016 Nov; 37(11):15133-15143. PubMed ID: 27677286
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
